In response to the global COVID-19 pandemic, the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) at the Bloomberg School of Public Health redirected a portion of the Alan and Helene Goldberg In Vitro Toxicology Grants to development of tools to address the emerging health threats. This new initiative is our Fast-track grant for research on non-animal approaches to investigate mechanisms, medicines, and vaccines for coronaviruses.
You can find further details about the grant awardees here.
We would like to thank Animalfree Research, Humane Society International, and Humane Society of the United States for their generous financial support of these grants.
CAAT received 60+ applications, and all were of high quality, making the decision difficult. We would like to thank all of those who applied, and—if further funding should become available—may consider awarding additional applicants. The awardees and finalists are listed below.
Senior Scientist, Programme in Molecular Medicine
Hospital for Sick Children
Development of a platform for SARS-CoV-2 therapy testing and development using primary nasal epithelial cultures
Co-founder, President and CEO
GC Therapeutics, Inc.
Investigating the effects of hypertension drugs on the Infectivity of SARS-CoV-2 in synthetically accelerated vascularized type II pneumocyte-containing pulmonary organoids
- Nina Bhardwaj
Icahn School of Medicine at Mount SinaI
- Joaquin Dopazo
Fundacion Progreso y Salud
- Yotam Drier
Hebrew University of Jerusalem
- Stagljar Igor
Mediterranean Institute for Life Sciences
- Sergei V. Kotenko
Rutgers, The State University of New Jersey
- Maike Windbergs
Goethe University Frankfurt
More information about the grants and the awardees, including abstracts, may be found here.
From CAATwalk Newsletter, July 27, 2020: News and Updates from CAAT (Center for Alternatives to Animal Testings), https://caat.jhsph.edu/